Topics

Roche wins Tecentriq immunotherapy cocktail to treat NSCLC subgroup

05:42 EST 4 Dec 2019 | SmartBrief

Roche announced that the FDA has approved its immunotherapy candidate Tecentriq.  -More

Original Article: Roche wins Tecentriq immunotherapy cocktail to treat NSCLC subgroup

NEXT ARTICLE

More From BioPortfolio on "Roche wins Tecentriq immunotherapy cocktail to treat NSCLC subgroup"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...